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EXPLORING THE CONFORMATIONAL LANDSCAPE OF 
BIOACTIVE SMALL MOLECULES 
 
 




By using a combination of classical Hamiltonian Replica Exchange with high-level quantum 
mechanical calculations on more than one hundred drug-like molecules we explored here the 
energy cost associated with binding of drug-like molecules to target macromolecules. We found 
that, in general, the drug-like molecules present bound to proteins in the Protein Data Bank (PDB) 
can access easily the bioactive conformation and in fact for 73% of the studied molecules the 
“bioactive” conformation is within 3kbT from the most stable conformation in solution as 
determined by DFT/SCRF calculations. Cases with large differences between the most stable and the 
“bioactive” conformations appear in ligands recognized by ionic contacts, or very large structures 
establishing many favorable interactions with the protein. There are also a few cases where we 
observed a non-negligible uncertainty related to the experimental structure deposited in PDB. 
Remarkably, the rough automatic force-field used here provides reasonable estimates of the 
conformational ensemble of drugs in solution. The outlined protocol can be used to better estimate 
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Binding of a ligand to a macromolecule is a complex procedure involving not only direct ligand-
macromolecule interactions, but also changes in solvation and internal free energy of the interacting 
partners. Based on the conformational changes required for binding three different recognition 
modes have been suggested 1–3 i) Fisher’s lock and key, ii) conformational selection and iii) induced 
fit. In the first model, the unbound and bound conformations of both ligand and macromolecule are 
the same and no significant change in internal energy is associated with binding. In the other two 
models, binding implies rearrangements in the ligand, the protein or both. Within the 
conformational selection paradigm, the free energy cost associated with such transitions is small 
and the bioactive conformation is sampled spontaneously within the “unbound” conformational 
ensemble. On the contrary, according to the induced fit mechanism, the “bioactive” conformation 
is rarely populated in the unbound state and it appears just as a result of the ligand-macromolecule 
interactions. The design of efficient binders represents always a compromise between rigidity, 
which reduces the entropy cost associated to binding and flexibility that increases the possibility of 
favorable ligand-protein interactions. In general 4,5 bioactive small molecules (such as 
pharmaceutical drugs) have a limited number of rotatable bonds, suggesting a similarity between 
the unbound and bioactive conformations, but a non-negligible number of highly potent binders 
show a large number of rotatable bonds, raising the question of how different is the unbound 
conformational ensemble with respect to the bioactive conformation. Several authors suggest that 
adopting bioactive conformation implies a large energy penalty for the drug, while others support 
the idea that the bioactive conformation is sampled spontaneously in the unbound state as powerful 
binders are pre-organized to facilitate binding 6–11. With all these views in mind, we present here an 
automatized multilevel strategy, which combines fast exploration of the conformational space by 
means of classical Hamiltonian Replica Exchange (HREX) molecular dynamics (MD) calculations with 
high-level quantum mechanical (QM) calculations in aqueous solution. The approach is validated on 
a large set (115) of diverse bioactive small molecules (see Methods). In more than 97% of the cases 
the bioactive conformation (that one in which the drug binds the protein) is sampled in the HREX 
simulations (there is at least 1 of the collected snapshots with RMSd< 1 Å from the bioactive 
conformation). When the conformational space is reduced to a limited number of clusters (from 10 
to 40) the bioactive conformation is at less than 2 Å of one cluster in more than 96% of the cases; if 
the cutoff is reduced to 1.2 Å, the bioactive conformation is close to a cluster in 63% (10 clusters) 
and 79% (40 clusters) of the cases. In other words, the strategy used here seems to sample quite 
exhaustively the ligand conformational space. 
Our data suggest that the bioactive conformations are typically not the most populated (MD) or the 
lowest energy (QM) states in aqueous solution, but in around 70% of the cases the bioactive 
conformation is within 3 kbT from the most stable QM conformer in solution (60% of the cases 
difference below 2 kbT). This indicates that Fisher’s lock & key and conformational selection models 
dominate binding paradigm in our dataset of drug-protein small.  In about 10% of the cases, we 
observed large (> 5 kbT) energy differences between the most populated conformer in solution and 
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the bioactive one. Cases with large differences between the most stable and the “bioactive” 
conformations correspond to in general to ligands recognized by ionic contacts and/or establishing 
a wide network of interactions with the protein. Remarkably, for a few cases where the energy 
penalty associated with the adoption of the bioactive conformation is especially large, we observed 
some potential uncertainties related to the experimental structure deposited in PDB, which 
recommend a critical analysis of PDB-reported conformations.  
 
METHODS 
Data set. We have initially selected a data set of a total 123 pharmaceutically relevant ligands whose 
structures, complexed with at least one protein target, are known experimentally. Selected 
molecules include a subset (resolution ≤ 2.5 Å) of Perola’s dataset (80 ligands 4), 24 dual binders 12, 
14 pharmaceutical compounds with especial complexity (6 of them GPCR ligands) 13 and 5 bioactive 
macrocycles 14–18. Analysis of the set reveals that at least in 8 of these cases the bioactive 
conformation reported in PDB might be partially incorrect (see Suppl. Figure 1 and below). Thus, to 
avoid bias in the results, these 8 structures were removed leading to a final set of 115 compounds 
(see below). The set corresponds to a wide range of chemical structures (see Figure 1 for details of 
database composition), molecular weight (from 200 to 700 g/mol), flexibility (from 1 to 12 rotatable 
bonds), hydrogen bonding capabilities (from 0 to 12 H-bond donors and/or acceptors) and ionic 
states (at pH 7.4 46% of the ligands are expected to be neutral, 29 % anions and 25 % cations). 
 
Figure 1 Details of database composition. A) Molecular weight of ligands B) Distribution of 





Ligand preparation. We extract the ligands (with resolution ≤ 2.5 Å) from the corresponding PDB 
files and determine the placement of the hydrogens at physiological pH using Open Babel 19 and 
Marvin Sketch 20 checking the consistency of their assignments in view of the drug-protein 
recognition mode (just a few cases with errors in the annotation were found). Antechamber tool 21 
and Acpype 22 open source codes were used to assign rough Generalized Amber Force Field (GAFF) 
parameters 23 and to define topologies to the ligands. Atomic charges of the ligands were 
determined at AM1-BCC level 24. Each ligand was solvated in a truncated octahedron box of TIP3P 
water molecules 25 (periodic boxes were selected to guarantee a minimum distance greater than 8 
Å from the ligand to the closest face). The systems were neutralized by adding suitable ions, 
minimized, thermalized and equilibrated for 1 ns (at constant pressure and temperature (1 atm, 298 
K). 
Enhanced sampling simulations. After several tests including unbiased MD, annealing and 
Temperature replica exchange MD, we decided to accelerate sampling by using Hamiltonian Replica 
EXchange (HREX) 26,27 using GROMACS 4.6.7 28 patched with PLUMED 2.1 29,30 and the Gromacs HREX 
implementation 31. We used 16 replicas and scaling all the atoms (charge; epsilon Lennard-Jones 
parameter; proper dihedral) of the solute (Replica Exchange with Solute Tempering, REST2) 32 with 
values of λ ranging from 1 to 0.59 following a geometric distribution (1, 0.966086, 0.933324, 
0.901672, 0.871095, 0.841554, 0.813015, 0.785442, 0.758806, 0.733075, 0.708214, 0.684196, 
0.660993, 0.638578, 0.616921, 0.596). Production runs were evolved at 298 K in the NVT ensemble 
with the velocity rescaling thermostat. The acceptance rate ranged from 60% to 90%. Exchanges 
were attempted every 500 steps. Each replica ran for 10 ns with accumulative sampling time of 
160ns per compound, taking data every 1 ps. Particle Mesh Ewald (PME) 33 and periodic boundary 
conditions were used to represent long-range electrostatic effects. All bonds linking hydrogens were 
frozen using SHAKE 34, which allowed us the use of 2 fs time scale for integration of Newton 
equations of motion. By default the statistics was extracted from the non-scaled replica (λ=1). 
Simulations took typically between 6 and 12 hours in a small Intel Xeon E5-2670 @ 2.60GHz cluster 
using 1 processor per replica. Computational times are compatible with the high-throughput 
timescale required for drug-design projects. The workflow is shown in Figure 2, while further details 




Figure 2 Scheme of the automatic pipeline 
 
Clustering. The ensembles collected from the 104 snapshot trajectories were analyzed to define the 
most populated clusters. After testing different clustering approaches, we follow Daura’s algorithm 
35 as implemented in GROMOS. Accordingly, internal RMSdi was used as metrics, counting the 
number of neighbors (within a given cut-off) for each structure, and taking that with the largest 
number of neighbors as a center of cluster.  Cluster representative was determined as the structure 
with the lowest RMSD among a family. Clusters were mutually exclusive and were annotated by 
using an iterative clustering approach, making sure that they represent at least 95% of the total 
sampled space. Application of this general clustering strategy, which would be very efficient for 
peptides, leads to some problems for our small drug-like molecule, where regional symmetry can 
exist. To avoid these problems standard Daura’s clustering annotation is refined by: i) using a 
symmetry-corrected dihedral metrics 36 37 (dAB; dihMetrics, eq.1) ii) re-group clusters which are 
identical based on the new metrics, iii) re-annotate snapshots to clusters based on the dihedral 
metrics measured with respect to the centroid. Detailed explanation of the method and formula are 
provided in Suppl. Info. All the post-process and refinement methodology was implemented with R 
scripts 38. Analysis of several examples showed us that this procedure defines clusters with a robust 
well-defined population and containing snapshots with similar geometries (see detailed analysis 
below). 
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where 𝑛 is the number of dihedrals that are used to compute the distance and 𝜑 = 𝜑 − 𝜑 , 
where Si is the symmetry number of torsion i, 𝜑  and 𝜑  are the values of the dihedral 𝑖 in the 
structure 𝐴 and 𝐵, respectively (see Suppl. Information for additional details). 
High level calculations. The geometries of cluster representatives were used as a starting point for 
quantum mechanical calculations. After preliminary tests we decided to perform a two-steps 
geometry optimization: first, the geometries of the cluster representatives for each ligand were 
optimized at IEF-MST/HF/3-21G level, using the output as starting point for further IEF-
MST/B3LYP/6-31G(d) geometry refinement as implemented in Gaussian 39,40. IEF-MST calculations 
were done considering water as solvent and the associated cavity and van der Waals parameters 41. 
The final optimized geometries were used for additional single-point calculations at the M06-
2X/aug-cc-pVDZ level 42 taking in this case the solvation contribution from the B3LYP/6-31G(d) 
calculation 43–45. To explore potential errors in the DFT treatment, additional calculations were 
performed at the MP2/aug-cc-pVDZ level 46,47 for a selected set of 14 molecules.  
Defining the bioactive conformations. The conformations directly extracted from PDB have in 
several cases major structural distortions (see examples in Suppl. Figure S1), forcing us to relax the 
geometry to obtain realistic bioactive conformations. Our first approach was to fix the dihedral 
angles at the X-ray values, pre-optimize the geometry by AM1/MST 48,49 calculations and perform 
further refinement by IEF-MST/B3LYP/6-31G(d) calculations 40,41. This procedure leads to partially 
relaxed geometries, very close to the X-Ray ones, but with less structural artefacts. Unfortunately, 
not all obvious distortions were corrected, as some torsional angles led to artefactual internal 
geometries (see examples in Suppl. Figure S1). We decided then to relax all the degrees of freedom, 
assuming that the PDB structure is close to a local minimum. For 86% of the ligands the bioactive-
relaxed geometry is quite close to the X-ray structure (RMSd< 1 Å; see Suppl. Figure S2); the 
remaining 18 cases were analyzed in detail. For 4 of these 18 ligands the X-ray conformation is 
supported by electron density, and we adopt then the partially-relaxed (dihedral fixed) 
conformation for the remaining analysis; in 6 cases, human inspection shows that relaxed and X-Ray 
structures are not so different in terms of the bound moiety (i.e. most differences affect solvent-
exposed moieties) and we maintain then the relaxed geometry as bioactive conformation. Finally, 
in 8 cases, X-Ray conformation leads to unlikely geometries, which are not supported by electron 
densities; to avoid biases these cases were removed for future analysis. As shown in Figure S2, the 
final dataset contains 115 molecules, the bioactive conformations considered here deviate in 
general around 0.5 Å from the X-ray structure in the PDB. 
The cost of reaching the bioactive conformation. There are many ways of defining the cost of 
reaching the bioactive conformation. Taken the MD ensembles and assuming that the “bioactive 
conformation” is reached when the “bioactive cluster” is sampled, the free energy cost associated 
to moving from the aqueous ensemble to the “bioactive conformation” is given by eq. 2: 







where T is the temperature, kb is the Boltzmann constant and  𝑃  is the population of the “bioactive 
cluster” referred to the total population of the ensemble, 𝑃 . An additional estimate of the free 
energy penalty associated to reaching the bioactive state (defined as the “bioactive cluster”) is 
defined from the difference in stability between the most stable cluster and the bioactive one, see 
eq. 3: 





where 𝑃  is the population of the most stable cluster, i.e. the most populated one in the MD 
ensemble. 
Note that the annotation of the “bioactive cluster” is arbitrary depending on the threshold radii 
used for the assignment of the bioactive conformation (see below), i.e. on how close a conformation 
should be to that found in the crystal to be considered bioactive. Accordingly, for threshold radii 
different to 0 the estimates obtained using eqs. 3 and 4 represent most likely lower boundary values 
of the (free) energy cost required to adopt the bioactive conformation. 
At the quantum level we can obtain a QM/SCRF estimate of the strain (free) energy by using (eq. 4): 




where index 0 refers to the most stable conformer in solution (as defined by QM/SCRF calculations) 
and index b refers to the bioactive conformation (obtained as described above). A discrete quantum 
alternative to eq. 2 can be formulated assuming the width associated to all clusters is equivalent 
(i.e. assuming entropy within a cluster is the same) by using eq. 5: 
 ∆𝐺 = 𝐺 + 𝑘 𝑇 𝑙𝑛 𝑒  (5) 
 
where the sum extends for all the k clusters (k≠b) defining the conformational space of the unbound 
ligand. Note that eqs. 4 and 5 are exact for an infinite number of clusters, but in practice implies an 
upper boundary limit for the (free) energy cost associated to achieving the bioactive conformation 
as most likely the bioactive cluster is typically narrower than the others. 
Data accessibility. All data is available at the Bioactive Conformational Ensemble (BCE) server 
http://mmb.irbbarcelona.org/BCE/ (see companion paper ct-2020-00305q). Trajectories were 




RESULTS AND DISCUSSION 
 
Robustness of the sampling protocol. After several tests using different enhanced sampling 
approaches, we chose HREX as sampling method for its efficiency 26,51 and for the easiness to 
implement it into a general automated workflow. We tested the convergence of the approach to 
the extension of the simulation trajectory (16 replicas) for 6 representative drugs showing different 
conformational complexity. Results summarized in Figure 3 demonstrate that extension of the 
simulation time leads to only small changes in the population of the clusters. This, and the similarity 
between the cluster representatives obtained from different simulation times (data not shown) 
suggest the HREX procedure used here in conjunction with 10 ns x replica window is accurate 
enough to explore conformational space.  
 
Figure 3 Population of clusters as a function of the simulation length: 10 ns (blue), 50 ns (orange), 
and 100 ns (gray) is shown. The analysis shows that cluster population is robust with respect to the 
simulation length and that 10 ns are enough to observe converged cluster. Analysis are performed 
for (A) the pdb ligand 1afq-0FG with 9 rotatable bonds; (B) 2pix-FLF with 3 rotatable bonds, (C) 1jsv-
U55 with 3 rotatable bonds and D) 1qhi-BPG with 6 rotatable bonds. See Suppl. Figures S3-S4 for 
additional convergence tests. 
Analysis of the entire dataset shows that the bioactive conformation is sampled in the HREX 
simulation (there is at least 1 of the collected snapshots with RMSd < 1 Å from the bioactive 
conformation; see Figure 4) in more than 97% of the cases. This indicates that the selected strategy 



























space of drugs in aqueous solution, and extension of the simulation times and replica numbers 
seems justified only for drugs containing many rotatable bonds and potential interacting groups. 
Robustness of the clustering protocol. As we cannot re-compute all the sampled conformations at 
the QM level, clustering is crucial to derive representative structures from the HREX samplings. We 
applied an iterative clustering algorithm with a maximum of 10 clusters representing at least 95% 
of the snapshots. Cluster annotation was performed (see Methods) correcting symmetry-related 
biases. In general, we found that even with a reduced 10-cluster representation, there is one cluster 
closer than 2 Å to the bioactive conformation in more than 96% of the cases (Figure 4). Even with a 
very strict cutoff (1.2 Å) the chances to have bioactive conformation close to a cluster are large (from 
63% to 79% depending on the number of clusters selected). In summary, the clustering approach 
seems robust enough to simplify the ligand conformational ensemble. 
 
 
Figure 4 Robustness of the sampling and clustering protocol. The analysis shows that with HREX 
sampling, there is at least 1 of the collected snapshots with RMSd < 1 Å from the bioactive 
conformation (blue color). Chances to have bioactive conformation close to a cluster are calculated 
for different size of ensembles: maximum 10 cluster representatives (orange), 20 (grey) and 40 
(yellow) cluster representatives.  
 
Convergence of the QM results. Any high-throughput QM technique requires the use of a medium 
or low-level QM calculation, whose accuracy needs to be validated against experiments or higher-





















31G(d), and M06-2X/aug-cc-pVDZ (see Methods) and for a selected set of 14 diverse molecules, we 
repeated calculations at a high correlated level (MP2/aug-cc-pVDZ), always using the same solvation 
model (MST; see Methods). Taken the 14 molecules together, (i.e. more than 120 conformational 
energies compared), the average energy RMS deviations between the MP2 and the DFT profiles are 
below 2 kbT (B3LYP) or 1 kbT (M06-2X) (see Figure 5). Differences are greater than 3 kbT only for 
three molecules at the B3LYP/6-31G(d) level, and none if M06-2X/aug-cc-pVDZ are used. In 
summary, DFT methods provide results that are reasonably close to the reference MP2 ones, even 
when lower level B3LYP/6-31G(d) calculations are considered.  
 
Figure 5 Convergence of the QM results. The average energy RMS deviations between the MP2 and 
the DFT profiles B3LYP/6-31G(d) (blue) and M06-2X/aug-cc-pVDZ (grey).  
Divergence between MM and QM cluster representatives. As described in Methods, cluster 
representatives were selected and re-optimized at the QM level (B3LYP/6-31G(d)) with MST 
description of the solvent 41. This optimization leads to new geometries which are in general 
between 0.2 and 0.8 Å from the MM cluster representative (see Figure 6), with no cluster shift 
detected during the process. In summary, cluster representatives are close to a local minimum in 
the SCRF/QM space and accordingly the sampling obtained from Hamiltonian replica exchange can 




Figure 6 Divergence between MM and QM cluster representatives. RMS [Å] between MM and QM 
optimized cluster showing there is no cluster shift detected during the SCRF/QM minimization.  
Population of the bioactive conformation. As noted above, for more than 96% of molecules we can 
annotate the bioactive conformation to one of the 10 representative clusters (cutoff 2 Å), but only 
in   ̴20% of the cases the “bioactive cluster” is the most populated one. Free energy penalties ∆𝐺  
and ∆𝐺  (eqs. 1 and 2) depend, obviously, on the threshold used to define the “bioactive 
cluster” and on the number of clusters used to summarize drug conformational space (see Figure 
7). For the default choice of 10 clusters and a cut-off of 2 Å ∆𝐺  values below 4 kbT and ∆𝐺  
below 3 kbT are obtained in more than 90% of the cases (Figure 7). All these findings suggest that 
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Figure 7 Free energy penalties ∆𝐺  and ∆𝐺  with different thresholds used to define the 
“bioactive cluster” and on the number of clusters used to summarize drug conformational space. 
(light blue) 10 clusters and a cut-off of 1.2 Å ; (orange) 10 clusters and a cut-off of 2.0 Å; (grey) 20 
clusters and a cut-off of 1.2 Å; (yellow) 20 clusters and a cut-off of 2.0 Å; (dark blue) 40 clusters and 
a cut-off of 1.2 Å; (green) 40 clusters and a cut-off of 2.0 Å 
To confirm the small magnitude of the free energy cost associated to the adoption of the bioactive 
conformation we analyze QM/SCRF estimates of “distortion” and “strain” (free) energies as shown 
in eqs. 3 and 4. Very interestingly (see Figure 8 A and B), the relaxed bioactive structure (see 
Methods) is the most stable conformer (∆𝐺 =0) in close to 40% of the studied cases. Around 
60% of the studied ligands show strain energies below 2 kbT, and only 10% of the studied ligands 
show strain energies above 5kbT. These numbers are quite robust to the DFT functional and basis 
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Figure 8 Top: QM/SCRF estimation of ∆𝐺  at B3LYP/6-31G(d) (orange) and M06-2X/aug-cc-
pVDZ level (purple). Figure (A) represents the cumulative plot while (B) is histogram. Bottom: 
QM/SCRF estimation of ∆𝐺  at B3LYP/6-31G(d) (green) and M06-2X/aug-cc-pVDZ level (red). 
Figure (C) represents the cumulative plot while (D) is histogram. 
Small changes in the analysis occur if distortions (eq. 4) instead of strain (eq. 3) free energies are 
considered (Figure 8 C and D). In summary, after analyzing a large dataset of drug-like molecules we 
can conclude that the cost of moving the ligand from solution to the “bound” conformation is 
reasonably small and accordingly “bioactive state” can be easily sampled in solution (Figure 8). This 
suggests that, in the dataset of ligand-protein complexes analyzed here, Fisher’s lock & key and 
conformational selection are the prevalent mechanisms for binding. However, caution is required 
to extrapolate this finding, as we cannot ignore that we are analyzing a set of high affinity binding 
compounds, which means that induce-fitting events are probably underrepresented. Finally, it is 
worth noting that the general agreement between classical and QM/SCRF calculations provide 
confidence on the quality of the rough force-field used here in the classical MD simulations to 
describe reasonably well the ligand conformational space. 
The exceptions to the rule. As noted above, most of the studied molecules can easily achieve the 
bioactive conformation, but we cannot ignore that there is a non-negligible number of cases where 
the bioactive state is a very unlikely conformation of the unbound ligand. We manually analyzed all 
these cases that escape from the (ligand-wise) Fisher’s lock-and-key model (10% of cases with 
∆𝐺  > 5 kbT and/or ∆𝐺  > 6 kbT at the QM/SCRF level; see Figure 9). Different situations were 
found (see examples in Figure 9). In some cases, the distorted part of the ligand in the protein-
complex is located in a region where no electron density appears (for example the linker in 4dru-
0LN, the pentyl arm in 4fgl-CLQ, or the piperidine moiety in 3ebp-CPB) and we cannot discard a 
problem with the annotated X-Ray conformer. Other cases can be explained by the existence of 
complex protein-ligand network of hydrogen bonds or salt bridges, which stabilize polar moieties in 
the ligand at arrangements that are not the optimum ones in the unbound state in solution (ex. 
1ohr-1UN, 1eve-E20, 1f0t-PR1, 1ydt-IQB, 1htf-G26, 4dpf-0LG). These interactions are usually 
shielded from the solvent, thus suggesting an effective way to stabilize the ligand-protein complex 
upon ligand binding. For example, in the HIV- 1 protease-inhibitor systems 1ohr-1UN and 1htf-G26, 
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the hydroxyl group of the inhibitors is embedded into the catalytic dyad establishing charge-
reinforced H-bond interactions with two Asp (D25) residues while two carbonyl groups (and an 
amine) interact with the NH backbone via partially buried H-bonds. Clearly, H-bonds and 
electrostatic ligand-protein interactions can favor ligand conformations that would be otherwise 
rarely populated in solution. Very interesting is the 1mq6-XLD case, where the amino-oxazolin 
moiety is in a distorted conformation packed between Trp215, Phe174 and Tyr99 a site that reproduces 
a cation-pi pocket, suggesting the ring might be protonated, not neutral as was originally assumed 
based on rough pKa calculations.  
 
Figure 9 Examples of the exceptions to the rule. a) 4dru-0LN, missing electron density b) 4fgl-CLQ, 
missing electron density c) 1ohr-1UN, in the complex with the receptor (HIV protease), the OH is 
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embedded into the catalytic dyad D25 (from two monomers), d) 4dpf-0LG, our most stable 
conformation closely resemble the bioactive one except for the protonated nitrogen of the ethyl 
amino group, typical of BACE1 inhibitors, e) 1f0t-PR1, the molecule is well tethered within the 
receptor with the pirrolidinic group H-bonding the receptor NH of backbone G219, f) 1mq6-XLD, 
where the amino-oxazolin moiety is in a distorted conformation packed between Trp215, Phe174 and 
Tyr99 a site that reproduces a  cation-pi pocket.  
Overall molecules with net charge show slightly larger strain and distortion energies than the neutral 
ones, but differences are in general small (Figure 10). Molecular weight is not a good descriptor to 
predict the cost of adopting the bioactive conformation, as heavy molecules can contain very rigid 
portions (Figure 10). The number of rotatable bonds seems a better descriptor of the cost of moving 
to the bioactive conformation as seen in Figure 10. Taking molecules with 10 or less rotatable bonds 
(data for 11-12 rotatable bonds are too limited in our set of compounds) ∆𝐺 = 0.4 · 𝑘 𝑇 · 𝑁  
and ∆𝐺 = 0.5 · 𝑘 𝑇 · 𝑁 ; both in kcal/mol. Unfortunately, while these equations are accurate 
for average values (Pearson’s correlation around 0.85 in both cases; n=9), they are not so predictive 
at the individual level (Pearson’s coefficient around 0.4 (strain) and 0.5 (distortion); n= 107), due to 
the vast dispersions of values in molecules with the same number of rotatable bonds (for example 
for Nrot=5 ∆𝐺  range from 0 to 10 kbT). Clearly, well-positioned H-bond and electrostatic ligand-
protein interactions can favor ligand conformations that would be otherwise rarely populated in 
solution (in a companion paper (ct-2020-00305q) we provide the community with a database and 
webserver that would enable drug discoverers to apply the methodology used in this work to their 
small molecule(s) of interest). However, these cases are rare and the design of new more active 
drugs should keep in mind conformational energy considerations, as a very active drug is likely to 






Figure 10 Dependence of the QM/SCRF strain ∆𝐺  and distortion energy  ∆𝐺  with properties 
of the ligand.  A) ∆𝐺  against number of rotatable bonds (flexibility) of the ligand (blue) and 
∆𝐺  against number of rotatable bonds (flexibility) of the ligand (grey);  B) ∆𝐺  against charge 
(blue) and ∆𝐺  against charge (grey);  C) Dependence of the QM/SCRF strain ∆𝐺  (blue) and 
distortion energy  ∆𝐺  (grey) with molecular weight. Note that when possible, data are grouped 
to have a similar number of compounds (marked in the histogram bars) for each category. Large 
standard deviations are related to cases with unusually large strain energies (see “The exceptions 
to the rule section” and Figure 9).  
 
CONCLUSIONS 
The availability of our Bioactive Conformational Ensemble (BCE) server and database allowed us to 
explore the ability of a very large set of drug-like ligands to adopt the bioactive conformation as 
described in crystal structures in PDB. The result of a comprehensive analysis showed us that: 
o Caution is necessary before assuming structures of ligands deposited in PDB are always 
accurate representations of bioactive conformations. In some cases, assumed 
“experimental” structures are incompatible with basic chemical principles. In others, 
unusual arrangements are not supported by direct experimental observables, but are likely 
to be the result of a too simplistic modeling. Clearly, refinement of PDB using high-level 



































































o Enhanced sampling techniques such as Hamiltonian Replica Exchange coupled with rough-
automatic force-fields allow a comprehensive exploration of the ligand conformational 
space, the “bioactive” conformation being typically sampled during the simulations. 
o Rough force-fields such as GAFF, which are easy to incorporate into automatic pipelines, 
provide results which are better than anticipated. When coupled to advanced enhanced 
sampling techniques allow the sampling of bioactive state in most cases. 
o Simple B3LYP/6-31G(d)/MST calculations provide results of enough quality as compared 
with those obtained by more recent DFT functionals or MP2 calculations. We cannot rule 
out certain SCRF-related biases in the predicted conformations in solution, especially for 
heavily charged ligands but it seems that simple DFT/SCRF calculations are accurate enough 
as to provide a good description of conformational states in solution and can be safely used 
to predict potential bioactive states and eventually to correct automatic force-fields. 
o There are many cases where the bioactive conformation is the most stable conformation in 
QM/SCRF calculations, and in the (free) energy penalty required to adopt the bioactive 
conformations is typically small. Cases with large distortion energies can be explained by 
the existence of many favorable protein-ligand contacts. 
o Overall, it seems that good ligands, as those present in PDB, have conformational 
preferences facilitating their binding. In terms of the ligand, Fisher’s lock and key and 
conformational selection models seem prevalent  in the analysed dataset  and accordingly, 
accurate determination of ligand preferred conformational states is crucial for any 
structure-based drug design exercise. Whereas significant, we note that the analyzed drug-
like complexes are biased and not exhaustive, thus not suitable for conclusive remarks on 
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